Uncategorized Archives - Page 18 of 248

ThursdayJun 22, 2023 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Findings in Diabetes Animal Study and Two Other R&D Programs

Diabetes – Blood glucose levels reduced by 19.9% with patented DehydraTECH(TM) processed CBD Epilepsy – Lower dosages of DehydraTECH-CBD were needed to achieve the same results of Epidiolex(R) in the company’s animal epilepsy study Dementia – Lexaria determined that a longer testing duration is needed for DehydraTECH-CBD in cognition studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, including the company’s patented DehydraTECH(TM) technology, recently reported additional findings from its diabetes animal study DIAB-A22-1, as well as updates on two other applied R&D programs for dementia (DEM-A22-1) and epilepsy (EPIL-A21-1). In March, Lexaria announced that it had…

ThursdayJun 15, 2023 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) May Announcements Show Resolve to Continue Supporting R&D ‘Lifeblood’

In May, Lexaria made a number of positive announcements related to its R&D initiatives In addition to holding its 2023 Annual Meeting, the company completed dosing for its human clinical nicotine study, NIC-H22-1 Lexaria also reported 900% improvements in delivery of DehydraTECH(TM) processed estrogen into blood plasma in an animal study In a human hypertension study, the company announced that its DehydraTECH-CBD formulation resulted in significant reductions in the blood plasma levels of pro-inflammatory biomarkers (IL 8, 10, and 18) These biomarkers are linked to cardiovascular disease (“CVD”) and many other conditions, such as asthma, lung diseases, chronic kidney disease,…

WednesdayJun 14, 2023 4:20 pm

420 with CNW — Bruen Ruling Could Bring Good Tidings to Marijuana Movement

A 2022 ruling by the Supreme Court has radically changed a century-old U.S. gun law and significantly altered how courts assess gun laws. Judges in the New York Rifle and Pistol Association v. Bruen overturned a 100-year-old gun safety law and ruled that a New York law requiring licenses to conceal carry weapons in public was unconstitutional. The overturned New York gun law was strikingly similar to gun safety laws in seven other states, and the June 2022 ruling set a precedent for overturning these laws. In the aftermath of the Supreme Court ruling, judges in several states overturned gun…

FridayJun 09, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields Most Convincing Evidence for Anti-Inflammatory Actions of CBD with its DehydraTECH(TM)-CBD

Lexaria just announced additional findings from its HYPER-H21-4 human clinical study, highlighting significant reductions in several pro-inflammatory biomarkers associated with cardiovascular disease This has been termed as “the most convincing evidence in humans,” ultimately showcasing the potential of the company’s patented DehydraTECH(TM)-processed CBD Other third-party research studies have failed to demonstrate a sustained decrease in resting blood pressure with oral CBD dosing. More so, none have yielded evidence of the anti-inflammatory actions of CBD until Lexaria’s HYPER-H21-4 human clinical study Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced additional findings from its HYPER-H21-4 human clinical…

ThursdayJun 08, 2023 4:20 pm

420 with CNW — Proposed California Law Could Legalize Marijuana Cafes

The wave of cannabis reform that has swept across America over the past two decades doesn’t seem to be stopping any time soon. By April 2023, nearly 40 states had medical marijuana markets while close to two dozen states allowed recreational cannabis sales. California legalized recreational cannabis in November 2016 and was soon generating billions of dollars in revenue and state tax from adult-use cannabis sales. With California now home to what is undoubtedly the largest cannabis market in the world, state lawmakers are currently working on a bill that would legalize marijuana cafes and allow the sale of both…

MondayJun 05, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Animal Study Showing Its Patented DehydraTECH(TM) Technology Significantly Enhances Oral Delivery of Estradiol; Raises $2 Million in Gross Proceeds from Public Offering

Lexaria recently completed its animal study HOR-A22-1 showing its patented DehydraTECH(TM) technology dramatically enhanced the oral delivery of estradiol, a type of estrogen hormone The use of DehydraTECH resulted in ~900% higher peak concentration of estradiol in the bloodstream compared to the control, as well as a 2,000% increase in the levels of estrone Estrone is a type of estrogen that can be reversibly made from estradiol in certain tissues within the female body The study HOR-A22-1 also revealed that DehydraTECH resulted in 1,500% and 12,500% higher exposure to estradiol and estrone over time, respectively, compared to the control Lexaria…

WednesdayMay 31, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Finalizes DehydraTECH(TM)-CBD Batch Manufacturing for IND Filing This Summer and FDA Phase 1b Trial Commencement in October 2023

Lexaria just announced the completion of batch manufacturing of its patented DehydraTECH(TM)-processed CBD and placebo materials for its FDA Phase 1b HYPER-H23-1 human clinical study This is in line with the company’s IND filing with the FDA, which it looks to complete this summer, with potential authorization within 60 days FDA authorization will mark the commencement of Phase 1b trial patient dosing, with the study evaluating the safety and tolerability of DehydraTECH-CBD in hypertensive patients Filling into capsules of the manufactured DehydraTECH-CBD is expected to be completed before the end of this month, after which analytical release and stability testing…

FridayMay 26, 2023 10:30 am

The Green Label Expo: Las Vegas 2023 Edition

The Green Label Expo 2023 edition will be held at the World Market Center in Las Vegas on the 13th & 14th of September, welcoming thousands of CBD experts, alternative product professionals, counterculture experts, and business owners to discover a vast array of global suppliers in trending sectors such as beauty, health & wellness, pet products, foods, business services, and more. As the need for embracing alternative products surges, the vibrant city of Las Vegas is set to welcome the largest trade show for CBD and alternative product professionals. This two-day event will feature an extensive showcase of innovative products/services,…

FridayMay 26, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Shareholders Approve Board Appointments Amid Push for Diversity; Vote to Endorse 6 Agenda Items in 2023 Annual Shareholder Meeting

Lexaria held its virtual 2023 Annual Shareholders meeting on May 9, 2023 On the agenda were the election of six director nominees, the ratification of the appointment of the company’s independent registered public accounting firm, and the approval of a one-time repricing of specific issued stock options, among others All items presented received approval, with the highest approval percentage standing at 97.6% and the lowest at 63.1% The meeting presented an opportunity for Lexaria to evaluate areas of expertise that would provide additional benefits to the company and its shareholders while also adding diversity to its board Lexaria Bioscience (NASDAQ:…

TuesdayMay 23, 2023 11:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes $2 Million Public Offering Consisting of Common Shares and Accompanying Warrants

Lexaria recently completed its 2,106,000-unit public offering at $0.95 per share – representing proceeds totaling over $2 million gross in support of the company’s growth Maxim Group LLC is acting as the sole placement agent in connection with Lexaria’s offering Earlier the company was granted four new patents, bringing its total to 32 granted and many more pending worldwide for its patented DehydraTECH(TM) technology Lexaria is currently seeking IND status from the FDA for use of DehydraTECH-processed CBD with hypertension and expects to begin dosing a new human clinical trial in October 2023 Lexaria Bioscience (NASDAQ: LEXX), a global innovator…